IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Ridker, P.M., Devalaraja, M., Baeres, F.M., Engelmann, M.D., Hovingh, G.K., Ivkovic, M., Lo, L., Kling, D., Pérgola, P.E., Raj, D.S., Libby, P., &amp; Davidson, M. (2021). IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. <em>The Lancet</em>. https://doi.org/10.1016/s0140-6736(21)00520-1

Ridker PM, Devalaraja M, Baeres FM, Engelmann MD, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2021. doi:10.1016/s0140-6736(21)00520-1.

@unpublished{paul2021ILinhi, title = {IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial}, author = {Paul M. Ridker and Matt Devalaraja and Florian M.M. Baeres and Mads D.M. Engelmann and G. Kees Hovingh and Milana Ivkovic and Larry Lo and Douglas Kling and Pablo E. Pérgola and Dominic S. Raj and Peter Libby and Michael Davidson}, journal = {The Lancet}, year = {2021}, doi = {10.1016/s0140-6736(21)00520-1}, }